Medicure patents expiration
1. Aggrastat patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US5972967 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| US5733919 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| US5965581 | MEDICURE | Compositions for inhibiting platelet aggregation |
Oct, 2016
(7 years ago) | |
| US5978698 | MEDICURE | Angioplasty procedure using nonionic contrast media |
Oct, 2017
(6 years ago) | |
| US6136794 | MEDICURE | Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist |
Jan, 2019
(5 years ago) | |
| US6770660 | MEDICURE | Method for inhibiting platelet aggregation |
May, 2023
(11 months ago) | |
Drugs and Companies using TIROFIBAN HYDROCHLORIDE ingredient
Market Authorisation Date: 17 May, 2002
Treatment: A dosing regimen of aggrastat (tirofiban hydrochloride)(25mcg/kg followed by 0.15mcg/kg/min infusion) to reduce the rate of thrombotic coronary events associated with acute coronary syndrome (acs) in ...
Dosage: SOLUTION;INTRAVENOUS; SOLUTION;INJECTION; INJECTABLE;INJECTION
How can I launch a generic of AGGRASTAT before it's drug patent expiration?
More Information on Dosage
AGGRASTAT family patents
2. Zypitamag patents expiration
| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents protects the active chemical substance. Only drug patent owner can launch products that use this active substance. | ||||
| US8829186 | MEDICURE | Method for preparation of pitavastatin and pharmaceutical acceptable salts thereof |
Jan, 2031
(6 years from now) | |
Drugs and Companies using PITAVASTATIN MAGNESIUM ingredient
Market Authorisation Date: 14 July, 2017
Treatment: NA
Dosage: TABLET;ORAL
More Information on Dosage
ZYPITAMAG family patents